FDA Breakthrough Device Aortic Stenosis Screening Market

The ECG-based screening segment leads the FDA breakthrough device aortic stenosis screening market by technology with a 36.4% share in 2026. Hospitals account for 30.6% by end user, early detection represents 35.5% by application, and adults hold 69.0% of the age-group segment.